

IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
06600	SCICLONE PHARMA	2021/02/24	2021/03/02	2021/03/03

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit www.cfsg.com.hk or contact our account executives or customer service officers

Subscription Details via CASH Securities

Offer Period	2021/02/19-2021/02/24
Closing Time for Margin Application	2021/02/23 2:00pm
Subscription Fee	HKD 100
Days For Margin Financing	6 days
Indicative Interest Rate	2.98% #Eligible new and existing customers who successfully activate the electronic direct debit authorization (DDA) transfer service before the termination of the IPO subscription can enjoy a 0.25% loan interest reduction.

*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

SciClone Pharmaceuticals (Holdings) Limited (6600.HK)

Share Offer Highlights

Total Number of Offer Shares:	115,984,500 Shares (subject to the Overallotment Option)
- Number of Public Offer Shares:	11,599,000 Shares (subject to adjustment)
- Number of Placing Shares:	104,385,500 Shares (subject to adjustment and the Over-allotment Option)
Number of Shares per Lot:	500 Shares
Offer Price:	HKD 17.20 – 18.80 per Share
2019 Historical P/E ratio:	15.84x – 17.31x
Sponsor:	Morgan Stanley, CICC, CREDIT SUISSE

Company Overview

The Company is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the largest and fast-growing therapeutic areas with significant unmet medical needs in China, primarily including oncology and severe infection. Leveraging its integrated platform, it strives to develop and commercialize a portfolio of high-quality marketed products, including its proprietary product, Zadaxin, and pipeline drugs in its focused therapeutic areas. It primarily engage in the sales of (i) its proprietary product, Zadaxin; (ii) its in-licensed products; and (iii) promotion products on behalf of its business partners in China. In recent years, it started the development of a number of pipeline drug candidates. Its current portfolio of pipeline drug candidates contains not only some late-stage candidates, but also a number of earlystage candidates that have entered into Phase II clinical trial or earlier stage. During the Track Record Period and as of the Latest Practicable Date, it generated its revenue primarily from the sales of Zadaxin, which it rely on its CMO partner Patheon Italia to produce, to Sinopharm in China.

For the year ended December 31, 2017, 2018 and 2019 and the nine months ended September 30, 2020, the Company's net profits were RMB19.58 mn, RMB535.08mn, RMB614.60 mn and RMB689.76 mn respectively.

Source

IPO Prospectus

Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-21) 3227 9888
	Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(020) 8981 7463
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026



Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.